University of Helsinki researchers made a breakthrough in their discovery that a molecule known as BT13 has the potential as a therapeutic for Parkinson’s disease. In preclinical research studies including in vitro and in vivo studies in mouse models, the Finnish team...
A team led by University College London Institute of Neurology discovered ambroxol therapy could be used as a neuroprotective compound to treat patients with Parkinson’s disease both with and without glucocerebrosidase (GBA1) gene mutations. This study was sponsored...
The Feinstein Institutes for Medical Research has received U.S. Food and Drug Administration (FDA) approval for a new Positron Emission Tomography (PET) drug to combat Parkinson’s disease. Fluorodopa F 18 Injection (NDA 200655) will help visualize dopaminergic nerve...
There is tremendous value in identifying new purposes for existing drugs. Recently, Georgetown University Medical Center (GUMC) embarked on a project to do just that for Parkinson’s disease with a cancer drug called nilotinib (Tasigna). They found that the drug in...
Researchers from the Center for Neurogenetics and colleagues from the Northwestern University Feinberg School of Medicine report a novel small-molecule modulator called S-181 shows promise in preclinical research animal studies for the treatment of a familial form of...
Gene therapy is making a comeback in the world of neurodegeneration research, as evidenced by this year’s Society for Neuroscience conference held in Chicago. With the success of Novartis Zolgensma (gene therapy for spinal muscular atrophy in infants), money...
